MicrobiotiX Co., Ltd.
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
Antibiotic resistance is one of the greatest challenges in modern medicine, driving the urgent need for alternative treatments. Bacteriophage therapy offers a promising solution by using naturally occurring viruses that selectively target drug-resistant bacteria.
MicrobiotiX is at the forefront of this innovation, developing a bacteriophage-based treatment for pneumonia caused by resistant strains. Leveraging over 20 years of expertise in antibiotic resistance and phage research, our approach is led by Prof. Dongeun Yong of Yonsei University’s College of Medicine, a renowned expert in the field.
Our proprietary in silico screening platform—on one of the largest global libraries of clinically relevant bacteria and phages—enables us to identify optimal phage candidates with high precision, accelerating the drug development process. Additionally, our cGMP-compliant phage facility allows us to produce high-quality clinical-grade therapeutics in-house.
Company HQ City:
Seoul
Company HQ State:
Seoul Special Metropolitan City
Company HQ Country:
Korea, Republic of
Year Founded:
2016
Lead Product in Development:
MP101: a phage-based therapeutic targeting P. aeruginosa in HAP/VAP
CEO
Dongeun Yong
Year Founded
2016
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2; MP101 (P. aeruginosa HAP/VAP) and MP201 (NTM Lung Infections)
When you expect your next catalyst update?
IND approval by the Ministry of Food and Drug Safety in Korea
What is your next catalyst (value inflection) update?
October 2025
Website
www.microbiotix.net
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}